Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 9, Issue 7, Pages 635-640Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.8b00057
Keywords
HDAC inhibitor; HDAC inhibitor prodrugs; acute myeloid leukemia; hydrogen peroxide; peroxynitrite; reactive oxygen species
Categories
Funding
- Wayne State University startup fund
- Karmanos Cancer Institute Cancer Epigenetics Strategic Research Funding
Ask authors/readers for more resources
Occurrence of acute myeloid leukemia (AML) results in abundant endogenous reactive oxygen species (ROS)/reactive nitrogen species (RNS) in AML cells and in disease-relevant microenvironments. Histone deacetylase inhibitor (HDACi) prodrug approach was designed accordingly by masking the hydroxamic acid zinc binding group with hydrogen peroxide (H2O2)/peroxynitrite (PNT)-sensitive, self-immolative aryl boronic acid moiety. Model prodrugs 5-82 and 5-23 were activated in AML cells to release cytotoxic HDACis, evidenced by inducing acetylation markers and reducing viability of AML cells. Intracellular activation and antileukemic activities of prodrug were increased or decreased by ROS/PNT inducers and scavengers, respectively. Prodrugs 5-82 and 5-23 also enhanced the potency of chemotherapy drug cytarabine, supporting the potentials of this prodrug class in combinatorial treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available